New protocols based on ALK-targeted therapy by crizotinib or other ALK targeting molecules have opened for the treatment of NB patients in relapse if their tumors showed mutation and/or amplification of the ALK gene and new tumor sampling is strongly recommended at the time of relapse 23 for evaluating ALK mutational status given the observation that an emergence of ALK mutation might be seen at relapse. This evidence concerns the gene ALK and neuroblastoma.